Sanofi (SNY) Competitors

Sanofi (NASDAQ:SNY) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, community ranking, media sentiment and institutional ownership.

Does the MarketBeat Community believe in SNY or NVO?

Novo Nordisk A/S received 380 more outperform votes than Sanofi when rated by MarketBeat users. Likewise, 61.87% of users gave Novo Nordisk A/S an outperform vote while only 60.24% of users gave Sanofi an outperform vote.

Company	Underperform	Outperform
Sanofi	Outperform Votes 50 60.24%	Underperform Votes 33 39.76%
Novo Nordisk A/S	Outperform Votes 430 61.87%	Underperform Votes 265 38.13%

Is SNY or NVO a better dividend stock?

Sanofi pays an annual dividend of $1.47 per share and has a dividend yield of 2.7%. Novo Nordisk A/S pays an annual dividend of $1.57 per share and has a dividend yield of 2.1%. Sanofi pays out 59.0% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 47.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Which has better earnings & valuation, SNY or NVO?

Novo Nordisk A/S has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$44.29B	3.18	$6.02B	$2.49	22.27
Novo Nordisk A/S	$290.40B	1.14	$14.64B	$3.29	22.36

Which has more volatility and risk, SNY or NVO?

Sanofi has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500.

Do analysts rate SNY or NVO?

Sanofi presently has a consensus price target of $62.50, indicating a potential upside of 12.71%. Novo Nordisk A/S has a consensus price target of $145.25, indicating a potential upside of 97.43%. Given Novo Nordisk A/S's higher possible upside, analysts clearly believe Novo Nordisk A/S is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	3.00
Novo Nordisk A/S	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.80

Is SNY or NVO more profitable?

Novo Nordisk A/S has a net margin of 34.81% compared to Sanofi's net margin of 12.77%. Novo Nordisk A/S's return on equity of 84.68% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	12.77%	25.61%	14.72%
Novo Nordisk A/S	34.81%	84.68%	26.29%

Do insiders and institutionals have more ownership in SNY or NVO?

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Does the media prefer SNY or NVO?

In the previous week, Novo Nordisk A/S had 44 more articles in the media than Sanofi. MarketBeat recorded 78 mentions for Novo Nordisk A/S and 34 mentions for Sanofi. Sanofi's average media sentiment score of 0.88 beat Novo Nordisk A/S's score of 0.42 indicating that Sanofi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	15 Very Positive mention(s)	2 Positive mention(s)	12 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Novo Nordisk A/S	34 Very Positive mention(s)	6 Positive mention(s)	26 Neutral mention(s)	9 Negative mention(s)	3 Very Negative mention(s)	Neutral

Summary

Novo Nordisk A/S beats Sanofi on 13 of the 21 factors compared between the two stocks.